Ads
related to: bristol-myers squibbscbn.org has been visited by 10K+ users in the past month
Search results
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Motley Fool via Yahoo Finance· 5 days agoVertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates...
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend...
Benzinga· 3 days agoLoading... Loading... During times of turbulence and uncertainty in the markets, even when markets...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 days agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0225 ET...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 1 day agoAstraZeneca (AZN 0.91%), recognized as the world's sixth-largest pharmaceutical entity by market...
Uncovering the Unique Needs of Veterans Diagnosed With Cancer
Benzinga· 3 hours agoFlorida Cancer Specialists & Research Institute, LLC (FCS) recognizes the urgency in addressing disparities in care among the veteran oncology patient population when treatment is sought outside ...
Advances in CAR T-Cell Therapy for Multiple Myeloma
MedPage Today· 11 hours agoB-cell maturation antigen (BCMA)-directed CAR T-cell therapies are now established options for treating multiple myeloma after relapse, but efforts are...
HPV Vaccine Offers Cancer Protection Beyond Cervical Cancer
Medscape· 11 hours agoHPV vaccination protects not only against cervical cancer in women but also other HPV-related...
J&J antidepressant eases symptoms, improves sleep in key trial
BioPharma Dive via Yahoo Finance· 2 days agoDive Brief: A new kind of antidepressant eased symptoms and improved sleep among adults enrolled in...
Unprecedented PFS Results in ALK-Positive Lung Cancer Trial
MedPage Today· 11 hours agoFive-year results from a phase III trial had experts gushing over lorlatinib's (Lorbrena)...
Is It Too Late to Buy Vertex Pharmaceuticals Stock? | The Motley Fool
The Motley Fool· 5 days agoVertex Pharmaceuticals (VRTX 1.36%) is a fast-growing pharmaceutical company that investors have...